| Project/Area Number |
08557054
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
ICHIHASHI Masamitsu Kobe University, School of Medicine, Professor, 医学部, 教授 (00030867)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UTSUMI Hiroshi Kyoto University, Research Reactor Institute, Professor, 原子炉実験所, 教授 (20025646)
FUKUDA Hiroshi Institute of Development, Aging and Cancer, Tohoku University, Professor, 加齢医学研究所, 教授 (30125645)
SASAKI Makoto Core Engineering Department, Nuclear Energy Systems Engineering Center, Nuclear, 炉心技術部炉心計画課, 主査
KOBAYASHI Tooru Kyoto University, Research Reactor Institute, Professor, 原子炉実験所, 助教授 (90089136)
MISHIMA Yutaka Mishima Institute for Dermatological Research, Director Assistant, 所長
吉野 和夫 信州大学, 理学部, 助教授 (70143964)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Project Status |
Completed (Fiscal Year 1997)
|
| Budget Amount *help |
¥16,500,000 (Direct Cost: ¥16,500,000)
Fiscal Year 1997: ¥8,200,000 (Direct Cost: ¥8,200,000)
Fiscal Year 1996: ¥8,300,000 (Direct Cost: ¥8,300,000)
|
|---|
| Keywords | Boron / ^<12>B-BPA / Linear Accelerator / Epithermal / Melanoma / Thermal Neutron Capture Therapy / epithermal / melanoma / boron-10 / ^<10>B-p-bornophenylalanine / RBE / tyrosinase |
|---|
| Research Abstract |
It is difficult at present to treat melanoma patients by boron neutron capture therapy (BNCT), since machine time available for medical use is extremely limited.
Due to difficulty of constucting a new atomic reactor for medical use, we investigated a conceptual design for an accelerator-based BNCT facility.
We successfully designed a preliminary accelerator using Li as the target material, having beam power of 65-150 kW and beam current of 20 mA in 2.5 MeV or 10 mA in 10 MeV incident proton energy respectively which can produce enough thermal and epithermal neutron fluence for BNCT within 60 min.
^<10>B-BPA uptake increased in cells having higher melanin production by transfection of the tyrosinase gene, or the tyrosinase related protein-2 (TRP-2) gene. Technical improvements for transfecting the TRP-2 gene into melanoma cells in vivo remains to be studied further.
Combined thermal and epithermal radiation was proven to be effective in treating deeply-seated melanoma at 4 and 5 cm from the skin surface. By measuring ^<10>B content in tumor, blood and normal skin tissues of 23 patients with primary or metastatic melanoma who were operated on surgically or who underwent BNCT after receiving ^<10>B-BPA (85 mg/l kg or 170 mg/kg intravenous drip), the skin/blood ^<10>B ratio was found to be in the range of 1.2 and 1.5, and the tumor/blood ^<10>B ratio was also in the range of 3.0 and 4.0 within 6h after the end of administration. Further, kinetics of ^<18>F-labelled ^<10>B-BPA in melanoma metastasized into brain measured by positron emission tomography proved to be effective in estimating the ^<10>B content in melanoma tissue.
These results strongly indicate that BNCT for melanoma using ^<10>B-BPA has been significantly improved and has become a more efficient therapeutic modality for melanoma treatments, contributing to a better quality of life for melanoma subjects.
|
